<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>药筛 | wechat-feeds</title><link>http://Mzg5NTI5ODYzOA.favicon.privacyhide.com/favicon.ico</link><description>药品筛选</description><managingEditor> (hellodword)</managingEditor><pubDate>Mon, 22 Mar 2021 17:25:50 +0800</pubDate><image><url>http://Mzg5NTI5ODYzOA.favicon.privacyhide.com/favicon.ico</url><title>药筛 | wechat-feeds</title><link>http://Mzg5NTI5ODYzOA.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>海南普利 地氯雷他定独家剂型过评价 | 上周仿制药动态（3.15-3.21）</title><link>https://mp.weixin.qq.com/s/iasqKIGxTYB49lGuGKJY-A</link><description></description><content:encoded><![CDATA[海南普利 地氯雷他定独家剂型过评价 | 上周仿制药动态（3.15-3.21）]]></content:encoded><pubDate>Mon, 22 Mar 2021 16:44:46 +0800</pubDate></item><item><title>3个独家剂型品种过评价</title><link>https://mp.weixin.qq.com/s/e__LGlTRmXVm9EukfHPE-A</link><description></description><content:encoded><![CDATA[3个独家剂型品种过评价]]></content:encoded><pubDate>Wed, 17 Mar 2021 18:05:52 +0800</pubDate></item><item><title>尼达尼布、培美曲塞、地西他滨等多款抗肿瘤药过评价 | 上周仿制药动态（3.8-3.14）</title><link>https://mp.weixin.qq.com/s/bMLYq1NB33s8vr7Ei_iwNA</link><description></description><content:encoded><![CDATA[尼达尼布、培美曲塞、地西他滨等多款抗肿瘤药过评价 | 上周仿制药动态（3.8-3.14）]]></content:encoded><pubDate>Mon, 15 Mar 2021 16:37:20 +0800</pubDate></item><item><title>齐鲁又一特色品种获批，机会or挑战？</title><link>https://mp.weixin.qq.com/s/8nWEZxE3_0q3dGPy4Q2W8w</link><description></description><content:encoded><![CDATA[齐鲁又一特色品种获批，机会or挑战？]]></content:encoded><pubDate>Thu, 11 Mar 2021 19:25:18 +0800</pubDate></item><item><title>新批文、过评数创新高，相同品种扎堆  | 1、2月仿制药动态</title><link>https://mp.weixin.qq.com/s/6mDPAwF0-JdNyMpbV0J-UA</link><description></description><content:encoded><![CDATA[新批文、过评数创新高，相同品种扎堆  | 1、2月仿制药动态]]></content:encoded><pubDate>Tue, 09 Mar 2021 12:46:55 +0800</pubDate></item><item><title>金城金素 注射用头孢曲松钠第4家过评价 | 上周仿制药动态（3.1-3.7）</title><link>https://mp.weixin.qq.com/s/QawmBMgsCQkQRYXtToKCzQ</link><description></description><content:encoded><![CDATA[金城金素 注射用头孢曲松钠第4家过评价 | 上周仿制药动态（3.1-3.7）]]></content:encoded><pubDate>Mon, 08 Mar 2021 15:22:42 +0800</pubDate></item><item><title>艾力斯重磅一类新药伏美替尼获批，进军百亿市场</title><link>https://mp.weixin.qq.com/s/pRWu69SWQZAijeBCudg0SQ</link><description></description><content:encoded><![CDATA[艾力斯重磅一类新药伏美替尼获批，进军百亿市场]]></content:encoded><pubDate>Wed, 03 Mar 2021 17:34:23 +0800</pubDate></item><item><title>好政策，不亏待老实人</title><link>https://mp.weixin.qq.com/s/k529LbejTkpryBqDdu9Ngg</link><description></description><content:encoded><![CDATA[好政策，不亏待老实人]]></content:encoded><pubDate>Tue, 02 Mar 2021 18:31:47 +0800</pubDate></item><item><title>广东嘉博 丙泊酚中/长链脂肪乳过评价 | 上周仿制药动态（2.22-2.28）</title><link>https://mp.weixin.qq.com/s/n_RPabVQGIV_IroxOi2a9Q</link><description></description><content:encoded><![CDATA[广东嘉博 丙泊酚中/长链脂肪乳过评价 | 上周仿制药动态（2.22-2.28）]]></content:encoded><pubDate>Mon, 01 Mar 2021 18:58:15 +0800</pubDate></item><item><title>仅用5天，2新冠疫苗获批，国内已累计4款</title><link>https://mp.weixin.qq.com/s/4_LJpWmSUkble3MSPQ9KbQ</link><description></description><content:encoded><![CDATA[仅用5天，2新冠疫苗获批，国内已累计4款]]></content:encoded><pubDate>Thu, 25 Feb 2021 22:10:55 +0800</pubDate></item></channel></rss>